OXERVATE

(Cenegermin-Bkbj)

ApprovedSmall molecule

DDompé Farmaceutici S.p.A

OXERVATE is one of 57 small molecule programs targeting Keratitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

KeratitisCompleted

GrowthActive, not recruiting

KeratitisApproved

Completed

GrowthPreclinical

Active, not recruiting

Competition

Competitive Landscape

77 competitors in Growth

#DrugCompanyPhaseTrials

Growth Hormone

Pfizer

Phase 3

30 2

Neo-Synephrine

EExela Pharma Sciences, LLC.

Phase 3

1 3

OXERVATE

DDompé Farmaceutici S.p.A

Approved

1 4

Recombinant Human Growth Hormone

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

8 5

Fludara

Sanofi

Phase 1

1 6

Acipimox

Boehringer Ingelheim

Phase 2

1 7

Zyloprim

Jazz Pharmaceuticals

Preclinical

1 8

Lenvima

Eisai

Preclinical

1 9

Zolymbus

AbbVie

Preclinical

1 10

Aricept

Eisai

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Growth1 trial

Nerve Growth Factor for the Treatment of Cornea Disease

Completed·SStanford University··NCT04552730·5 enrolled

Treatment1 trial

NGF Treatment for Patients With Neuropathic Corneal Pain

Withdrawn·TTufts Medical Center·Phase 1·NCT05700864

Keratitis1 trial

Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis

Completed·DDompé Farmaceutici S.p.A·Phase 4·NCT04485546·37 enrolled

Regulatory

FDA Approval Timeline[4]

Aug 22, 2018

OXERVATE

BLA BLA761094

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Cenegermin-Bkbj. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cenegermin-Bkbj compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cenegermin-Bkbj. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761094). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Dompé Farmaceutici S.p.A company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: DDompé Farmaceutici S.p.A

OXERVATE

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Growth1 trial

Treatment1 trial

Keratitis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News